Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Change in Inventory (2023 - 2025)

Fennec Pharmaceuticals filings provide 3 years of Change in Inventory readings, the most recent being -$139000.0 for Q4 2025.

  • On a quarterly basis, Change in Inventory fell 113.85% to -$139000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 320.73% increase, with the full-year FY2025 number at $1.3 million, up 320.73% from a year prior.
  • Change in Inventory hit -$139000.0 in Q4 2025 for Fennec Pharmaceuticals, down from $276000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $797000.0 in Q2 2025 to a low of -$502000.0 in Q3 2024.
  • Median Change in Inventory over the past 3 years was $296000.0 (2023), compared with a mean of $189916.7.
  • Biggest five-year swings in Change in Inventory: plummeted 258.86% in 2024 and later skyrocketed 896.25% in 2025.
  • Fennec Pharmaceuticals' Change in Inventory stood at $401000.0 in 2023, then tumbled by 116.21% to -$65000.0 in 2024, then crashed by 113.85% to -$139000.0 in 2025.
  • The last three reported values for Change in Inventory were -$139000.0 (Q4 2025), $276000.0 (Q3 2025), and $797000.0 (Q2 2025) per Business Quant data.